A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04408638)

🧪 Interventions in This Study

• Obinutuzumab (DRUG)
• Glofitamab (DRUG)
• Rituxumab (DRUG)
• Tocilizumab (DRUG)
• Gemcitabine (DRUG)
• Oxaliplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (63 Sites)

Showing the first 25 of 63 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• Community Cancer Institute (CCI) — Fresno, California
• Baptist - MD Anderson Cancer Center — Jacksonville, Florida
• University of Maryland Medical Center — Baltimore, Maryland
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• University of Mississippi Medical Center — Jackson, Mississippi
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
• Icahn School of Medicine at Mount Sinai — New York, New York
• Duke University Medical Center — Durham, North Carolina
• Prince of Wales Hospital — Randwick, New South Wales
• Royal Adelaide Hospital — Adelaide, South Australia
• Monash Health Monash Medical Centre — Clayton, Victoria
• St Vincent's Hospital Melbourne — Fitzroy, Victoria
• Peter Maccallum Cancer Centre — Melbourne, Victoria
• Sir Charles Gairdner Hospital — Nedlands, Western Australia
• UZ Leuven Gasthuisberg — Leuven,
• CHU de Liège (Sart Tilman) — Liège,
• Peking University Third Hospital — Beijing,
• Sun Yet-sen University Cancer Center — Guangzhou,
• Harbin Medical University Cancer Hospital — Harbin,
• Fudan University Shanghai Cancer Center — Shanghai,
• Tianjin Cancer Hospital — Tianjin,
• Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology — Wuhan,
• Zhejiang Cancer Hospital — Zhejiang,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Diffuse Large B-cell Lymphoma

• Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients — Daphne, Alabama
• A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Tucson, Arizona
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas — Birmingham, Alabama
• A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) — Tucson, Arizona
• A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) — Rochester, New York
• Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma — Cleveland, Ohio

Explore by condition: All Diffuse Large B-cell Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.